高级检索
黄爱菊, 陈慧娟, 李进岚, 何昱颖, 陈璞, 杨婕, 荀梦君, 安露, 周军. 2011 — 2020年贵州省TB/HIV双重感染者流行趋势分析[J]. 中国公共卫生, 2023, 39(5): 633-638. DOI: 10.11847/zgggws1138095
引用本文: 黄爱菊, 陈慧娟, 李进岚, 何昱颖, 陈璞, 杨婕, 荀梦君, 安露, 周军. 2011 — 2020年贵州省TB/HIV双重感染者流行趋势分析[J]. 中国公共卫生, 2023, 39(5): 633-638. DOI: 10.11847/zgggws1138095
HUANG Aiju, CHEN Huijuan, LI Jinlan, . Prevalence and treatment of patients with TB and HIV co-infection in Guizhou province, 2011 – 2020[J]. Chinese Journal of Public Health, 2023, 39(5): 633-638. DOI: 10.11847/zgggws1138095
Citation: HUANG Aiju, CHEN Huijuan, LI Jinlan, . Prevalence and treatment of patients with TB and HIV co-infection in Guizhou province, 2011 – 2020[J]. Chinese Journal of Public Health, 2023, 39(5): 633-638. DOI: 10.11847/zgggws1138095

2011 — 2020年贵州省TB/HIV双重感染者流行趋势分析

Prevalence and treatment of patients with TB and HIV co-infection in Guizhou province, 2011 – 2020

  • 摘要:
      目的  了解贵州省2011 — 2020年结核杆菌/艾滋病病毒(TB/HIV)双重感染流行情况,为TB/HIV双重感染防控工作提供参考依据。
      方法   对贵州省2011 — 2020年9个市州的TB/HIV双重感染防治资料的登记报告率、双向筛查率、三间分布、治疗及转归情况进行描述性统计分析,对时间动态变化趋势进行趋势 χ2检验分析。
      结果   贵州省2011 — 2020年双重感染患者年均登记报告率为0.88/10万,总体呈波动上升趋势(P < 0.05)。症状筛查率平均为85.89%(198785/231444),胸片或痰检筛查率平均为70.02%(162052/231444),诊断TB的检出率平均为0.91%(2103/231444),呈逐年下降趋势(P < 0.05);HIV抗体检测率平均为89.89%(360993/401572),HIV阳性检出率平均为0.29%(1039/360993),P < 0.05。2019年双重感染患者达到最多(472例),2011年最低(178例); ≥ 15岁男性占绝大多数;遵义市双重感染患者数最多,其次是黔南州、安顺市,黔西南州最少。TB/HIV双重感染共检出3142例,治疗2820例,治疗率为89.75%;同时抗病毒和抗结核治疗、单纯抗病毒治疗、单纯抗结核治疗的治疗率分别为65.75%(2066/3142)、7.70%(242/3142)、16.29%(512/3142)。
      结论  贵州省双重感染筛查工作还需进一步做到系统、规范,双向筛查率有待提高,不断提高治疗依从性与成功治疗率,关注重点人群和地区。

     

    Abstract:
      Objective  To examine the prevalence of tuberculosis/human immunodeficiency virus (TB/HIV) co-infection in Guizhou province during 2011 – 2020 for providing evidence to prevention and control of the dual infection.
      Methods   The information on all registered TB, HIV/AIDS patients and the patients with dual infection of TB and HIV during the 10-year period were collected from a TB/HIV co-infection screening and management program conducted across the province. Describe statistics was performed on the extracted data and trend chi-square test was used to assess temporal variation in the co-infection prevalence.
      Results  Of the 231 444 registered HIV/AIDS patients, 85.89% (n = 198 785) and 70.02% (n = 162 052) had symptom and chest radiograph/sputum smear screening for TB; the prevalence rate of TB was 0.91% among all the registered HIV/AIDS patients and the annual prevalence rate showed a downward trend (P < 0.05). For a total of 401 572 registered TB patients, 89.89% (n = 360 993) had HIV antibody test and HIV antibody positive rate was 0.29% among the TB patients detected. The screening tests resulted in an average annual prevalence rate of 0.88/100 000 for dual infection with TB and HIV among all registered TB and HIV/AIDS patients in the province during the period and the rate showed an upward trend (P < 0.05). The number of co-infected patients was the highest in 2019 (n = 472) and the lowest in 2011 (n = 178). The majority of the co-infected patients were males aged ≥ 15 years and the patients distributed unevenly across the prefectures in the province. Of all the co-infected patients (n = 3 142 ), 2 820 (89.75%) received treatments and the proportion of the patients receiving therapy of anti-TB and HIV, anti-HIV alone, and anti-TB alone were 65.75% (n = 2 066), 7.7% (n = 242), and 16. 29% (n = 512), respectively.
      Conclusion   The screening on dual infection of TB and HIV needs to be improved among TB and HIV/AIDS patients and medication compliance of the co-infected patients should be promoted simultaneously, especially among the population in the regions with a higher risk of the co-infection.

     

/

返回文章
返回